Detailansicht

Wissensnetz

Person

Moshe Elkabets

Immunologe

Name	Moshe Elkabets
Ort	Israel
Beruf	Immunologe (charakteristischer Beruf)
Beziehung	Universiṭat Ben-Guryon ba-Negev
Datensatztyp	Person
GND-Nummer	1159592772
Datensatz-ID	1159592772
Beteiligt an alle anzeigen PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism Inference of long-range cell-cell force transmission from ECM remodeling fluctuations TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer Probing antibody surface density and analyte antigen incubation time as dominant parameters influencing the antibody-antigen recognition events of a non-faradaic and diffusion-restricted electrochemical immunosensor IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Moshe Elkabets

PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism

Inference of long-range cell-cell force transmission from ECM remodeling fluctuations

TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer

Probing antibody surface density and analyte antigen incubation time as dominant parameters influencing the antibody-antigen recognition events of a non-faradaic and diffusion-restricted electrochemical immunosensor

IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer